1. Aβ oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer’s disease
- Author
-
Natalia Salvadores, Ines Moreno-Gonzalez, Nazaret Gamez, Gabriel Quiroz, Laura Vegas-Gomez, Marcela Escandón, Sebastian Jimenez, Javier Vitorica, Antonia Gutierrez, Claudio Soto, Felipe A. Court, Universidad de Sevilla. Departamento de Bioquímica y Biología Molecular, Junta de Andalucía, Ministerio de Ciencia e Innovación (MICIN). España, Fondo Nacional de Desarrollo Científico y Tecnológico (Chile), Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias (Chile) Fondap, Instituto de Salud Carlos III, European Commission, Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (España), Universidad de Málaga, Ministerio de Ciencia e Innovación (España), Agencia Estatal de Investigación (España), and National Institutes of Health (US)
- Subjects
Memory Disorders ,Amyloid beta-Peptides ,Neuroprotection ,Pathology and Forensic Medicine ,Mice ,Cellular and Molecular Neuroscience ,Alzheimer Disease ,Necroptosis ,Animals ,Amyloid-β oligomers ,Microglia ,Neurology (clinical) ,Neurodegeneration ,Alzheimer’s disease - Abstract
Alzheimer's disease (AD) is a major adult-onset neurodegenerative condition with no available treatment. Compelling reports point amyloid-β (Aβ) as the main etiologic agent that triggers AD. Although there is extensive evidence of detrimental crosstalk between Aβ and microglia that contributes to neuroinflammation in AD, the exact mechanism leading to neuron death remains unknown. Using postmortem human AD brain tissue, we show that Aβ pathology is associated with the necroptosis effector pMLKL. Moreover, we found that the burden of Aβ oligomers (Aβo) correlates with the expression of key markers of necroptosis activation. Additionally, inhibition of necroptosis by pharmacological or genetic means, reduce neurodegeneration and memory impairment triggered by Aβo in mice. Since microglial activation is emerging as a central driver for AD pathogenesis, we then tested the contribution of microglia to the mechanism of Aβo-mediated necroptosis activation in neurons. Using an in vitro model, we show that conditioned medium from Aβo-stimulated microglia elicited necroptosis in neurons through activation of TNF-α signaling, triggering extensive neurodegeneration. Notably, necroptosis inhibition provided significant neuronal protection. Together, these findings suggest that Aβo-mediated microglia stimulation in AD contributes to necroptosis activation in neurons and neurodegeneration. As necroptosis is a druggable degenerative mechanism, our findings might have important therapeutic implications to prevent the progression of AD., This study was funded by grants from FONDECYT No. 3180341 (to NS); FONDECYT No. 1190518 and FONDAP program 15150012 (to FC); Instituto de Salud Carlos III (ISCiii) of Spain, co-financed by FEDER funds from European Union, through grants PI18/01556 (to JV), PI21/00914 (to JV), PI18/01557 (to AG) and PI21/00915 (to AG), CIBERNED (to JV and AG) and by Junta de Andalucia Consejería de Economía y Conocimiento co-financed by FEDER 2014-2020 through grants US-1262734 (JV), UMA18-FEDERJA-211 (AG), UMA20-FEDERJA-104 (I-MG) and P18-RT-2233 (to AG). Ministry of Science and Innovation (MICIN) State Research Agency grants PID2019-107090RA-I00 and Ramon y Cajal Program RYC-2017-21879 (to IMG) and grants from NIH R01AG059321 and R01AG061069 (to CS).
- Published
- 2022
- Full Text
- View/download PDF